histori
antivir
antiretrovir
therapi
recent
compar
mani
medic
therapi
includ
tradit
antibiot
pregnanc
given
prolifer
recent
agent
longterm
data
base
decis
manag
pregnanc
access
uptod
inform
critic
optim
safeti
care
mother
infant
gener
avoid
unnecessari
medic
first
trimest
still
prudent
judici
use
medic
later
pregnanc
sensibl
exposur
medic
pregnanc
toxic
fetu
gestat
agedepend
manner
medic
teratogen
certain
stage
first
trimest
may
safe
later
pregnanc
medic
later
pregnanc
may
metabol
effect
interfer
neonat
function
determin
safe
medic
use
pregnanc
must
take
consider
rel
need
use
certain
medic
possibl
inadvert
exposur
earli
pregnanc
unplan
pregnanc
articl
review
commonli
use
antivir
antiretrovir
agent
place
particular
emphasi
issu
regard
use
pregnanc
amantadin
rimantadin
relat
drug
use
treatment
influenza
mechan
action
drug
well
understood
believ
like
act
membran
fusion
inhibitor
rnadepend
rna
polymeras
inhibitor
amantadin
excret
unchang
urin
wherea
rimantadin
metabol
liver
main
describ
side
effect
central
nervou
system
base
includ
insomnia
impair
think
confus
inform
pregnanc
limit
amantadin
shown
teratogen
embryotox
effect
given
high
dose
rat
adequ
human
studi
conduct
infant
expos
amantadin
pregnanc
see
front
matter
cardiovascular
abnorm
list
food
drug
administr
fda
categori
c
drug
neuraminidas
inhibitor
activ
influenza
b
mechan
action
involv
crucial
step
life
cycl
influenza
b
viral
surfac
glycoprotein
hemagglutinin
bind
sialic
acid
residu
respiratori
epitheli
surfac
glycoprotein
necessari
initi
infect
viru
replic
also
attach
host
cell
way
neuraminidas
cleav
link
free
new
virion
zanamivir
oseltamivir
sialic
acid
analog
competit
inhibit
viral
neuraminidas
zanamivir
inhal
dri
powder
mg
inhal
twice
daili
day
oseltamivir
oral
drug
given
mg
oral
twice
day
day
major
side
effect
nausea
vomit
concern
respiratori
distress
associ
zanamivir
limit
pregnanc
data
anim
studi
show
minor
skelet
alter
rat
pregnant
rat
given
zanamivir
similar
find
pregnant
rabbit
given
oseltamivir
drug
fda
categori
c
human
data
given
rel
limit
indic
may
prudent
avoid
drug
pregnanc
main
nucleosid
antivir
agent
current
avail
acyclovir
valacyclovir
famciclovir
ribaviron
indic
use
medic
pregnanc
includ
treatment
seriou
herp
zoster
infect
primari
herp
simplex
infect
prophylaxi
term
women
recurr
herp
simplex
rare
case
hivinfect
immunocompromis
pregnant
women
treatment
cytomegaloviru
cmv
infect
ganciclovir
foscarnet
may
indic
current
usual
indic
cmv
therapi
pregnanc
even
prevent
vertic
transmiss
acyclovir
synthet
purin
nucleosid
drug
phosphoryl
viral
encod
thymidin
kinas
result
acyclovir
triphosph
product
competit
inhibit
viral
dna
polymeras
effect
interfer
viral
replic
mechan
action
result
mammalian
non
herp
virusinfect
cell
spare
effect
drug
acyclovir
activ
herp
simplex
virus
type
varicella
zoster
viru
epsteinbarr
viru
effect
vitro
cmv
usual
oral
dosag
rang
mg
five
time
per
day
herp
simplex
viru
infect
mg
five
time
per
day
varicella
zoster
infect
note
bioavail
oral
acyclovir
led
develop
compound
includ
valacyclovir
famciclovir
design
achiev
better
dose
regimen
indic
use
acyclovir
pregnanc
includ
lifethreaten
matern
infect
varicella
pneumonia
dissemin
herp
simplex
infect
treatment
sever
varicella
infect
often
warrant
matern
symptom
relief
use
acyclovir
near
term
suppress
recurr
genit
herp
also
evalu
current
consid
clinic
option
decreas
neonat
exposur
viru
deliveri
increas
likelihood
vagin
deliveri
acyclovir
mg
three
time
day
week
gestat
deliveri
shown
pharmacokinet
studi
pregnanc
requir
achiev
suppress
pregnanc
manufactur
glaxosmithklin
close
acyclovir
valacyclovir
pregnanc
registri
total
case
acyclovir
exposur
pregnancywith
first
trimesterwer
detail
increas
risk
congenit
defect
report
acyclovir
found
breast
milk
level
approxim
matern
plasma
note
neonat
treatment
acyclovir
rel
commonplac
infant
suspect
herp
simplex
herp
zoster
infect
although
acyclovir
seem
rel
safe
neonat
caution
regard
use
infant
dehydr
warrant
renal
clearanc
drug
valacyclovir
valin
ester
acyclovir
act
oral
prodrug
convert
vivo
acyclovir
subsequ
action
drug
ident
acyclovir
valacyclovir
indic
use
pregnanc
acyclovir
acyclovir
longer
histori
use
pregnanc
commonli
recommend
pharmacokinet
valacyclovir
pregnanc
evalu
late
pregnanc
mg
twice
day
compar
mg
three
time
day
acyclovir
acyclovirvalacylovir
registri
glaxosmithklin
contain
pregnanc
first
trimest
show
evid
increas
risk
congenit
defect
specif
toxic
data
valacyclovir
pregnanc
although
valacyclovir
seem
gener
welltoler
drug
report
high
dose
hivinfect
nonpregn
person
treat
cmv
diseas
show
shorter
surviv
rate
patient
valacyclovir
effect
seem
caus
thrombot
microangiopathi
level
toxic
report
studi
drug
nonhivinfect
individu
famciclovir
analog
prodrug
convert
vivo
penciclovir
activ
metabolit
penciclovir
monophosphoryl
viral
encod
thymidin
kinas
convert
penciclovir
triphosph
preferenti
inhibit
viral
dna
polymeras
penciclovir
triphosph
lower
affin
viral
dna
polymeras
acyclovir
longer
intracellular
halflif
activ
herp
simplex
virus
type
varicella
zoster
viru
use
hepat
b
epsteinbarr
viral
infect
investig
famciclovir
well
absorb
oral
result
bioavail
convert
activ
form
liver
clear
renal
gener
famciclovir
seem
welltoler
drug
minim
data
avail
toxic
pregnanc
indic
use
pregnanc
limit
indic
treatment
herp
simplex
varicella
zoster
infect
acyclovir
would
first
choic
treatment
human
safeti
data
pregnanc
studi
conduct
men
exposur
famciclovir
show
advers
effect
semen
paramet
ganciclovir
acycl
analog
nucleosid
guanosin
convert
intracellularli
viral
kinas
ganciclovir
triphosph
competit
inhibit
dna
polymeras
also
incorpor
viral
dna
give
second
rout
disrupt
dna
synthesi
mainli
use
treatment
cmv
infect
immunocompromis
patient
ganciclovir
use
primarili
intraven
formul
oral
bioavail
poor
data
exist
regard
safeti
pregnanc
anim
data
suggest
embryotox
mice
rabbit
howev
limit
data
human
exposur
transplant
patient
show
advers
effect
seem
drug
cross
human
placenta
possibl
toxic
exist
late
pregnanc
data
avail
neonat
studi
use
ganciclovir
cmvinfect
infant
proceed
provid
help
data
current
main
toxic
seen
studi
bone
marrow
suppress
seem
revers
import
earli
data
suggest
improv
stabil
hear
loss
cmvinfect
infant
ribavirin
nucleosid
analog
activ
rna
virus
use
clinic
children
aerosol
treat
respiratori
syncyti
viru
oral
agent
use
treatment
chronic
hepat
c
alon
combin
interferonalpha
recent
use
treatment
sever
acut
respiratori
syndrom
sar
debat
efficaci
standard
indic
use
pregnanc
inadvert
use
context
hepat
c
infect
therapi
treatment
lifethreaten
infect
sar
may
occur
experiment
anim
data
suggest
mutagen
activ
hamster
treat
ribavirin
develop
defect
limb
eye
brain
rat
develop
defect
brain
eye
data
prompt
ribavirin
consid
potenti
human
teratogen
recommend
pregnanc
strictli
avoid
women
medic
small
seri
nine
pregnant
women
treat
ribavirin
sever
measl
advers
infant
outcom
report
note
exposur
occur
first
trimest
alpha
interferon
natur
occur
protein
antivir
properti
interferonalpha
produc
fetal
tissu
may
play
role
pregnanc
mainten
interferon
use
mani
situat
treatment
neoplasm
chronic
hepat
c
immunopath
diseas
note
new
form
interferon
peg
interferon
modifi
form
polyethylen
glycol
coval
bound
compound
slow
inactiv
excret
current
peg
interferon
ribavirin
frontlin
therapi
hepat
c
although
reproductiveag
women
instruct
prevent
pregnanc
therapi
inadvert
pregnanc
occur
gener
toxic
interferon
includ
pyrexia
leukopenia
hypotens
fatigu
anorexia
depress
signific
side
effect
peopl
interferon
larg
molecul
limit
studi
suggest
like
unabl
cross
placenta
anim
data
regard
use
interferon
monkey
time
human
dose
suggest
act
abortifaci
case
report
exist
regard
success
pregnanc
women
treat
interferon
chronic
myeloid
leukemia
hepat
c
pregnanc
foscarnet
pyrophosph
analog
bind
revers
near
pyrophosph
bind
site
dna
polymeras
use
treatment
ganciclovirresist
cmv
infect
immunocompromis
person
foscarnet
poor
bioavail
administ
intraven
excret
kidney
associ
nephrotox
crystal
salt
deposit
also
associ
hypocalcemia
hypophatemia
side
effect
includ
nausea
genit
ulcer
seizur
data
regard
use
pregnanc
limit
administr
foscarnet
rat
seem
result
hypoplasia
dental
enamel
singl
case
report
foscarnet
treatment
pregnant
patient
week
gestat
indic
appar
advers
effect
infant
use
pregnanc
reserv
lifethreaten
infect
mother
foscarnet
reason
treatment
antiretrovir
therapi
pregnanc
becom
increasingli
import
issu
worldwid
popul
women
hiv
infect
dramat
increas
research
determin
million
women
infect
hiv
repres
adult
person
infect
alon
million
new
infect
women
although
demograph
replic
western
countri
incid
hiv
infect
women
canada
increas
greatli
new
infect
women
given
magnitud
diseas
health
social
econom
level
becom
even
crucial
understand
impact
therapi
research
establish
highli
activ
antiretrovir
therapi
capabl
increas
life
span
individu
infect
hiv
complic
drug
regimen
signific
shortand
longterm
toxic
use
antiretrovir
therapi
also
allow
dramat
prevent
mothertochild
transmiss
hiv
antenat
treat
women
baselin
less
gener
principl
antiretrovir
therapi
pregnanc
recommend
treatment
pregnant
woman
provid
health
need
per
adult
treatment
recommend
also
recommend
antiretrovir
therapi
given
women
decreas
risk
transmiss
hiv
mother
infant
base
data
support
effect
approach
ensur
treatment
minim
risk
antiretrovir
resist
develop
also
import
consid
possibl
unplan
pregnanc
treatment
regimen
given
reproductiveag
women
basic
principl
highli
activ
antiretrovir
therapi
haart
therapi
focu
treatment
given
optim
therapi
mother
diseas
prevent
transmiss
infant
compromis
mother
futur
abil
take
antiretrovir
agent
choic
time
drug
therapi
also
must
select
minim
toxic
infant
antiretrovir
manag
pregnanc
discuss
paper
excel
uptod
review
lay
us
approach
diseas
antiretrovir
manag
one
compon
hiv
care
pregnanc
care
must
incorpor
care
obstetr
manag
manag
comorbid
condit
eg
anemia
poor
nutrit
substanc
alcohol
use
coexist
medic
problem
eg
hepat
c
diabet
proper
evalu
fetal
statu
gener
manag
hiv
pregnanc
well
describ
recent
review
counsel
women
best
medic
take
pregnanc
one
must
tri
understand
uptod
toxicolog
inform
avail
antiretrovir
medic
inform
chang
rapidli
publish
articl
insuffici
recent
embryotox
fetal
toxic
data
prescrib
medic
pregnanc
data
review
expert
area
keep
date
new
rapidli
emerg
data
first
clinic
success
antiretrovir
agent
introduc
zidovudin
azt
zdv
retrovir
drug
class
agent
termin
action
revers
transcriptas
enzym
requir
convert
viral
rna
dna
integr
host
genom
sinc
introduct
zidovudin
mani
nucleosid
analog
develop
includ
didanosin
ddi
videx
zalcitabin
ddc
hivid
stavudin
zerit
lamivudin
epivir
abacavir
medic
use
singl
agent
dual
combin
regimen
found
insuffici
alon
suppress
viral
replic
prolong
period
resist
develop
rapidli
exampl
agent
resist
develop
quickli
although
agent
use
combin
azt
use
togeth
compet
intracellular
mechan
activ
combin
must
consid
care
potenti
side
effect
current
known
human
teratogen
syndrom
associ
use
nucleosid
analog
revers
transcriptas
inhibitor
use
zidovudin
monotherapi
extens
studi
regimen
pregnanc
shortand
longterm
followup
studi
year
age
utero
exposur
transient
anemia
neonat
signific
advers
effect
report
note
howev
prospect
studi
conduct
use
agent
human
first
trimest
multicent
studi
experi
dual
nucleosid
antiretrovir
therapi
reveal
evid
teratogen
worrisom
fetal
toxic
mitochondri
toxic
believ
relat
primarili
exposur
nucleosid
revers
transcriptas
inhibitor
drug
abl
bind
mitochondri
gamma
dna
polymeras
found
differ
organ
system
result
mitochondri
dysfunct
phenomenon
mitochondri
toxic
vari
base
individu
particular
antiretrovir
combin
durat
therapi
clinic
effect
adult
includ
myopathi
myelosuppress
pancreat
peripher
neuropathi
hepat
steatosi
reliabl
mitochondri
dna
assay
develop
serum
lactat
use
marker
mitochondri
toxic
mitochondri
function
significantli
affect
downstream
accumul
lactic
acid
clinician
investig
rais
concern
mitochondri
toxic
may
even
common
pregnant
women
adult
medic
limit
data
suggest
may
advers
effect
neonat
mitochondri
effect
utero
neonat
treatment
lactic
academia
observ
studi
case
report
fatal
lactic
acidosi
made
nucleosid
expos
neonat
recommend
dose
zidovudin
mg
everi
hour
mg
twice
daili
origin
studi
pregnanc
actg
use
mg
time
per
day
one
main
concern
bone
marrow
toxic
actg
studi
signific
toxic
note
women
zidovudin
monotherapi
macrocytosi
usual
occur
mild
anemia
often
note
nausea
headach
malais
common
zidovudin
favor
pharmacokinet
pregnanc
found
safe
earli
phase
ii
studi
activ
transport
across
placenta
equival
concentr
fetu
matern
circul
congenit
anomali
attribut
zidovudin
actg
studi
prior
safeti
studi
anim
studi
show
embryo
fetal
toxic
macaqu
treat
time
maxim
human
dose
increas
fetal
neonat
death
hematolog
alter
offspr
pregnant
mice
given
zidovudin
show
increas
rate
embryon
death
specif
malform
pattern
report
possibl
carcinogen
zidovudin
anim
studi
nation
cancer
institut
studi
show
increas
liver
lung
genitourinari
tract
tumor
offspr
mice
given
high
dose
azt
last
trimest
glaxowellcom
studi
lower
dose
simul
treatment
dose
show
increas
tumor
tumor
identifi
children
expos
azt
pregnanc
follow
year
monitor
matern
subsequ
neonat
blood
count
advis
mitochondri
dysfunct
concern
observ
children
treat
zidovudin
pregnanc
four
children
combin
zidovudin
lamivudin
develop
sever
neurolog
complic
die
isol
report
cardiomyopathi
studi
echocardiogram
perform
infant
whose
mother
treat
zidovudin
pregnanc
abnorm
seen
larg
survey
associ
mitochondri
dysfunct
mortal
among
expos
children
recommend
dosag
lamivudin
mg
oral
twice
daili
favor
side
effect
profil
mild
diarrhea
headach
nausea
major
concern
pharmacokinet
seem
affect
pregnanc
placent
transfer
excel
pregnant
rat
rabbit
given
time
human
dose
reveal
advers
effect
embryo
studi
rabbit
rat
reveal
embryo
lethal
high
dose
document
human
malform
studi
combin
therapi
phase
ii
studi
third
trimest
shown
favor
pharmacokinet
safeti
dual
therapi
nucleosid
primarili
zidovudin
lamivudin
show
minim
toxic
recommend
dosag
didanosin
mg
twice
daili
patient
weigh
kg
mg
twice
daili
patient
weigh
less
kg
side
effect
note
includ
pancreat
peripher
neuropathi
monitor
regardless
pregnanc
statu
current
special
concern
regard
embryo
fetal
toxic
recommend
dosag
zalcitabin
mg
oral
everi
hour
major
side
effect
peripher
neuropathi
teratolog
test
conduct
mice
reveal
decreas
fetal
weight
skelet
defect
given
high
dose
mgkgd
lower
dose
mgkgd
seem
produc
effect
placent
transfer
seem
occur
simpl
diffus
present
fetu
approxim
concentr
matern
circul
recommend
dosag
stavudin
mg
oral
twice
daili
patient
weigh
kg
mg
oral
twice
daili
patient
weigh
less
kg
major
side
effect
peripher
neuropathi
transfer
stavudin
across
placenta
passiv
result
concentr
fetu
matern
circul
exposur
earli
embryo
stavudin
inhibit
progress
blastocyst
stage
studi
pregnant
rat
rabbit
administ
time
human
serum
concentr
show
increas
birth
defect
recommend
dosag
abacavir
mg
twice
daili
seem
well
toler
except
risk
potenti
seriou
hypersensit
reaction
rechalleng
hypersensit
occur
never
done
crossresist
nucleosid
analog
revers
transcriptas
inhibitor
may
problem
human
placent
transport
studi
suggest
drug
transport
mother
fetu
better
data
avail
use
pregnanc
reserv
time
maternalfet
benefit
outweigh
risk
proteas
inhibitor
use
indinavir
sulfat
crixivan
saquinavir
fortavas
inviras
ritonavir
norvir
nelfinavir
mesyl
viracept
amprenavir
lopinavir
tenofovir
class
medic
uniqu
mode
action
inhibit
proteas
activ
proteas
enzym
critic
termin
matur
infecti
virion
viral
rna
convert
dna
integr
host
genom
transcrib
translat
cellular
protein
produc
larg
nonfunct
polypeptid
chain
refer
polyprotein
polyprotein
must
cleav
small
function
protein
matur
virion
produc
enzym
perform
cleavag
proteas
drug
class
differ
side
effect
profil
great
drug
interact
potenti
interact
inhibitor
induc
cytochrom
system
mani
concern
rais
effect
proteas
inhibitor
therapi
higher
risk
gestat
diabet
concern
regard
associ
low
birth
weight
one
specif
concern
rais
evid
ergotamin
toxic
proteas
inhibitor
treat
individu
ergot
deriv
use
manag
hemorrhag
pregnanc
may
concern
seem
repeat
studi
recommend
dosag
indinavir
mg
oral
everi
hour
although
twice
daili
regimen
also
use
dose
modif
requir
certain
drug
combin
signific
advers
effect
nephrolithiasi
monitor
care
pregnanc
one
report
occurr
pregnanc
known
nephrolithiasi
occur
fetu
utero
given
potenti
nephrotox
rais
concern
concurr
use
indomethacin
also
caus
oligohydramnio
medic
cytochrom
effect
may
result
signific
drug
interact
review
use
studi
perform
rat
rabbit
use
dosag
slightli
higher
human
dosag
reveal
evid
teratogen
overal
indinavir
seem
well
toler
pregnanc
recommend
dose
saquinavir
fortavas
mg
oral
three
time
daili
poor
bioavail
problem
signific
side
effect
diarrhea
abdomin
discomfort
nausea
rat
given
five
time
human
dose
rabbit
given
four
time
human
dose
embryo
toxic
report
small
seri
human
report
reveal
specif
problem
note
seem
littl
transfer
saquinavir
across
placenta
recommend
dose
ritonavir
mg
six
capsul
twice
daili
gradual
dose
escal
side
effect
includ
gastrointestin
disturb
circumor
paresthesia
mani
potenti
drug
interact
care
review
individu
concurr
medic
undertaken
development
toxic
studi
rat
time
human
dose
reveal
decreas
fetal
bodi
weight
rabbit
expos
time
human
dose
decreas
litter
size
decreas
fetal
weight
placent
transfer
describ
rat
pregnanc
registri
data
one
case
congenit
malform
note
firsttrimest
exposur
specif
problem
note
secondand
thirdtrimest
exposur
nelfinavir
becom
commonli
use
proteas
inhibitor
gener
benign
sideeffect
profil
selflimit
diarrhea
commonli
report
problem
usual
dose
nelfinavir
mg
twice
daili
anim
data
preclin
trial
includ
embryo
problem
rat
compar
human
serum
concentr
firsttrimest
exposur
report
note
congenit
defect
pregnanc
registri
limit
report
safeti
pregnanc
indic
individu
report
low
birth
weight
prematur
confirm
larger
studi
dose
amprenavir
twice
daili
mg
per
dose
given
eight
tablet
result
high
pill
burden
limit
safeti
data
regard
nonpregn
individu
nausea
diarrhea
headach
report
note
rash
uncommon
sever
one
case
stevensjohnson
syndrom
report
drug
seem
cross
placenta
vitro
studi
preclin
report
show
increas
abort
rabbit
defici
skelet
ossif
offspr
pregnant
rabbit
limit
data
avail
pregnanc
registri
one
child
born
defect
firsttrimest
exposur
lopinavir
market
combin
ritonavir
kaletra
dosag
usual
mg
capsul
oral
twice
daili
lopinavirritonavir
combin
show
increas
congenit
malform
pregnant
rat
neither
agent
seem
cross
placenta
publish
data
human
current
avail
use
pregnanc
avoid
tenofovir
recent
approv
proteas
inhibitor
limit
pregnanc
data
avail
usual
dose
mg
daili
limit
data
show
seem
cross
placenta
monkey
without
evid
congenit
anomali
concern
chang
fetal
bone
poros
matern
monkey
studi
also
seen
administr
juvenil
monkey
publish
human
studi
drug
noncompetit
inhibitor
revers
transcriptas
enzym
requir
convers
viral
rna
dna
neveripin
viramun
delaverdin
rescriptor
efavirenz
sustiva
three
drug
current
common
use
current
antiretrovir
drug
medic
shown
effect
success
suppress
viral
replic
alon
dual
combin
nucleosid
analog
revers
transcriptas
inhibitor
usual
adult
dose
nevirapin
mg
daili
week
mg
twice
daili
side
effect
includ
gastrointestin
symptom
rash
anim
studi
preclin
trial
suggest
embryotox
teratogen
registri
data
suggest
evid
increas
birth
defect
firsttrimest
expos
human
pregnanc
preval
birth
defect
firsttrimest
exposur
safeti
toxic
evalu
limit
thirdtrimest
exposur
find
suggest
serum
level
similar
nonpregn
adult
hivnet
studi
use
singledos
nevirapin
mother
deliveri
infant
birth
studi
reveal
advers
effect
concern
use
nevirapin
pregnanc
risk
seriou
lifethreaten
hepat
toxic
report
nonpregn
individu
must
evalu
pregnanc
unpublish
report
seriou
life
threaten
complic
pregnanc
warrant
care
monitor
pregnanc
recommend
dose
delaverdin
mg
three
time
daili
rodent
given
high
dose
observ
develop
ventricular
septal
defect
current
data
avail
regard
human
pregnanc
earli
report
premarket
studi
seven
unplan
pregnanc
report
result
three
ectop
pregnanc
three
live
birth
one
infant
small
ventricular
septal
defect
efavirenz
dupont
merck
conduct
teratolog
studi
efavirenz
pregnant
anim
studi
rat
rabbit
given
dose
efavirenz
approxim
blood
level
achiev
human
given
mgd
fetal
malform
observ
studi
conduct
pregnant
monkey
fetus
deliv
cesarean
section
signific
malform
observ
cleft
palat
microphthalmia
anencephali
anophthalmia
data
avail
human
case
report
myelomeningocel
human
infant
born
woman
receiv
efavirenz
first
trimest
import
drug
avoid
first
trimest
pregnanc
particularli
requir
care
consider
use
reproductiveag
women
new
drug
novel
class
antiretrovir
agent
fusion
inhibitor
act
inhibit
bind
hiv
host
cell
wall
agent
requir
subcutan
administr
anim
data
reveal
earli
evid
embryotox
teratogen
primat
human
data
avail
known
agent
cross
placenta
effect
antiretrovir
agent
combin
difficult
sort
studi
examin
effect
combin
data
show
variabl
result
studi
report
seriou
matern
toxic
includ
hepatotox
higher
rate
neonat
malform
prematur
low
birth
weight
seriou
neonat
complic
includ
mitochondri
toxic
mani
studi
conduct
howev
includ
metaanalysi
suggest
gener
seriou
effect
mother
infant
interest
observ
decreas
risk
preeclampsia
hivinfect
women
restor
usual
rate
haarttreat
women
find
requir
explor
summari
greater
need
understand
effect
antivir
antiretrovir
therapi
pregnant
women
fetus
therapi
develop
enter
medic
practic
